Stay updated on Azacitidine and Pembrolizumab in MDS Clinical Trial
Sign up to get notified when there's something new on the Azacitidine and Pembrolizumab in MDS Clinical Trial page.

Latest updates to the Azacitidine and Pembrolizumab in MDS Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content or functionality of the page.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe webpage has undergone significant changes, including the removal of detailed information about a Phase II trial studying the combination of azacitidine and pembrolizumab for myelodysplastic syndrome, while retaining some identifiers and collaborators related to the study.SummaryDifference55%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check88 days agoChange DetectedThe page now indicates that some NLM-NCBI services and products are experiencing heavy traffic, which may impact their performance and availability. Additionally, the status of a service has been updated to 'Unknown' and a previous status of 'Active, not recruiting' has been removed.SummaryDifference2%
Stay in the know with updates to Azacitidine and Pembrolizumab in MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Azacitidine and Pembrolizumab in MDS Clinical Trial page.